Bayer and Onyx Pharmaceuticals have resolved a longstanding dispute over the rights to a Nexavar follow-up drug. Bayer will pay $160 million plus royalties and give co-marketing rights to Onyx in return for control of the new drug's development and commercialization. Their partnership on Nexavar is mostly unchanged, the companies said. Release | News